The paper describes how Cellzome’s quantitative chemical substance proteomics system was used to recognize a small molecule which plays a critical function in the regulation of the Wnt pathway. The small molecule stabilizes axin by inhibiting the poly-ADP-ribosylating enzymes tankyrase 1 and tankyrase 2. Both tankyrase isoforms interact with a highly conserved domain of axin and stimulate its degradation through the ubiquitin-proteasome pathway. Thus, the study provides new mechanistic insights into the regulation of axin protein homeostasis and presents brand-new avenues for therapeutic intervention in this important cancer tumor pathway.The company reported net earnings due to Bristol-Myers Squibb of $609 million, or $0.37 per talk about, in the quarter compared to $1.1 billion, or $0.64 per share, this past year. The business reported non-GAAP net income attributable to Bristol-Myers Squibb of $679 million, or $0.41 per talk about, in the initial quarter, in comparison to $1.1 billion, or $0.64 per talk about, for the same period in 2012. An overview of specified items is discussed under the ‘Use of Non-GAAP Financial Info’ section.